Analysis

Medicines Discovery Catapult: improving collaborative drug discovery in the UK

Medicines Discovery Catapult: improving collaborative drug discovery in the UK

Therapeutic orphans: child-friendly drugs and the quest for adherence

Therapeutic orphans: child-friendly drugs and the quest for adherence

BenevolentAI: using artificial intelligence to speed up drug discovery

BenevolentAI: using artificial intelligence to speed up drug discovery

The Hive: new incubator makes a beeline for non-traditional pharma companies

The Hive: new incubator makes a beeline for non-traditional pharma companies

Pharma Technology Focus – Issue 55

Pharma Technology Focus – Issue 55

After the cure: addressing side effects in childhood cancer patients

After the cure: addressing side effects in childhood cancer patients

Antibiotic resistance: the race for the prize

Antibiotic resistance: the race for the prize

Could activating telomerase trick the ageing process?

Could activating telomerase trick the ageing process?

Back to biology: how BERG is using artificial intelligence to tackle cancer

Back to biology: how BERG is using artificial intelligence to tackle cancer

IBM’s lab on a chip breakthrough seeks out cancers origin

IBM’s lab on a chip breakthrough seeks out cancers origin

US Precision Medicine Initiative gears up for a massive e-health drive

US Precision Medicine Initiative gears up for a massive e-health drive

Is the stage set for global drug price regulation?

Is the stage set for global drug price regulation?

August's top stories: Pfizer-AstraZeneca $1.5bn deal, Cinven buys Bioclinica for $1.4bn

August's top stories: Pfizer-AstraZeneca $1.5bn deal, Cinven buys Bioclinica for $1.4bn

At long last, a good year for Australia’s pharma industry

At long last, a good year for Australia’s pharma industry

Pharma Technology Focus – Issue 50

Pharma Technology Focus – Issue 50

Xilonix: new anti-tumour cancer drug is on the fast-track

Xilonix: new anti-tumour cancer drug is on the fast-track

ChemoFilter: getting the drugs back out

ChemoFilter: getting the drugs back out

Psilocybin vs. depression: London study overcomes obstacles to show encouraging results

Psilocybin vs. depression: London study overcomes obstacles to show encouraging results

Watching the clock: should day and night influence our drug regimens?

Watching the clock: should day and night influence our drug regimens?

July's top stories: Cancer Drugs Fund implemented in UK, Nichi-Iko acquired Sagent Pharmaceuticals

July's top stories: Cancer Drugs Fund implemented in UK, Nichi-Iko acquired Sagent Pharmaceuticals

The drug company tackling disease in Lebanon’s packed refugee camps

The drug company tackling disease in Lebanon’s packed refugee camps
cachename:Featurescachekey:rd-137342983_989685772_rd-1665407042_727740091_rd-488908060_1460672566_ap1460672566_727740091_-1939411708